Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
RBI Uses $10 Billion Currency Swaps to Drain Excess Rupee Liquidity 
Tencent Launches TenPayGo Payment App for Foreign Tourists in China 
OpenAI Agent Breaches Australia Medicare Data Portal 
Goldman Sachs Names Simon Lyons UK Investment Banking Co-Head 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
Meta Unveils Muse Charm AI Device, Expands Smart Glasses Lineup 
Apple Extends Qualcomm Patent Licensing Deal 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
Add as a preferred source on Google
Samsung Biologics and AstraZeneca are reportedly dissolving their biosimilar joint venture. They have formed the Archigen Biotech for the JV, and now this is being shut down.
An official of Samsung Biologics, the biotech unit of the Samsung Group, said on Tuesday, May 24, that it has decided to end its joint venture with the British-Swedish multinational pharmaceutical and biotechnology company due to the suspension of the development of a biosimilar product.
According to Yonhap News Agency, the decision came two months after the Samsung Biologics’ board agreed with the liquidation of Archigen Biotech Ltd. The said company was set up in 2014 via a 50-50 joint venture with AstraZeneca.
When it was first established, Archigen Biotech was working on the development of SAIT101, a biosimilar of Rituximab, a monoclonal antibody medication used for the treatment of lymphoma. It was explained that a biosimilar is a similar duplication of an already existing and approved biologic drug.
However, both Samsung Biologics and AstraZeneca halted the biosimilar program and scrapped the Rituxan copy project. It was revealed to have been actually discontinued in the second half of 2020 after competitors such as Celltrion Inc. started marketing the same products.
Fierce Pharma further reported that Archigen Biotech already launched a phase 3 trial of the SAIT101 in June 2016, but the works have been progressing very slowly. In fact, the original target date for the completion of the project has already been pushed back by more than a year.
The results of the trial were revealed last month and showed that the Rituxan biosimilar medication generated a response in 66.3% of patients, which is on par with the 70.6% posted by the originator.
But then, another issue has cropped up - the market for this product is already crowded with other biotech firms introducing their own biosimilars, with some already being sold. Aside from Celltrion, Achigen Biotech is also competing with Teva Pharmaceuticals, Pfizer, Mylan, and Novartis’ Sandoz. With all of these firms, it became apparent to Samsung Biologics and AstraZeneca that the best move now is to scrap their own Rituxan biosimilar product.
